Mobile App for Gynecologic Cancer Support for Patients With Gynecologic Cancer Receiving Chemotherapy in China: Multicenter Randomized Controlled Trial
Journal of Medical Internet Research · 2023
DOI: 10.2196/49939 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Internet Research, 2023. Verfasst von Huicong Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Xiamen University, Xiamen, Fujian Province, China. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Mobile Applications. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with gynecologic cancer receiving chemotherapy often report unmet supportive care needs. Compared with traditional face-to-face clinical interventions, mobile health can increase access to supportive care and may address patients’ needs. Although app-based support programs have been developed to support patients with gynecologic cancer, their efficacy has not been adequately tested.
Objective
The aim of this study was to examine the efficacy of a mobile app for gynecologic cancer support (MGCS) for patients with gynecologic cancer receiving chemotherapy in China.
Methods
A multicenter randomized controlled trial was conducted in 2 university-affiliated hospitals in China. A total of 168 Chinese patients with gynecologic cancer were recruited and randomized to receive routine care or MGCS program plus routine care for 24 weeks. The Mishel uncertainty in illness theory guided the development of MGCS program, which has 4 modules: weekly topics, emotional care, discussion center, and health consultation. The primary outcome of this program was the assessment of the uncertainty in illness. The secondary outcomes were quality of life, symptom distress, and social support. All health outcomes were evaluated at baseline (T0), 12 weeks (T1), and 24 weeks (T2). Repeated measures analysis of covariance was used to assess the efficacy of the MGCS program.
Results
In this trial, 67 patients in the control group and 69 patients in the intervention group completed 2 follow-up assessments (response rate, 136/168, 81%). At 12 weeks, no significant differences were observed in any of the health outcomes between the 2 groups. At 24 weeks, compared to patients in the control group, those in the intervention group reported significant decreased uncertainty in illness (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Xiamen University, Xiamen, Fujian Province, China.
- Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian Province, China.
- Department of Gynecology and Obstetrics, Zhongshan Hospital, Xiamen University, Xiamen, Fujian Province, China.
- Department of Nursing, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
- Department of Nursing, First Affiliated Hospital, Xiamen University, Xiamen, Fujian Province, China.
- President Office, Tung Wah College, Hongkong, China.
ORCID-Profile: Huicong Lin, Mingzhu Ye, Yanjuan Lin, Fuhong Chen, Sally Chan, Hongxia Cai, Jiemin Zhu
Zitieren
APA
Lin, H., Ye, M., Lin, Y., Chen, F., Chan, S., Cai, H., & Zhu, J. (2023). Mobile App for Gynecologic Cancer Support for Patients With Gynecologic Cancer Receiving Chemotherapy in China: Multicenter Randomized Controlled Trial. Journal of Medical Internet Research. https://doi.org/10.2196/49939
Vancouver
Lin H, Ye M, Lin Y, Chen F, Chan S, Cai H, et al. Mobile App for Gynecologic Cancer Support for Patients With Gynecologic Cancer Receiving Chemotherapy in China: Multicenter Randomized Controlled Trial. Journal of Medical Internet Research. 2023. doi:10.2196/49939
BibTeX
@article{Lin2023,
author = {Lin, Huicong and Ye, Mingzhu and Lin, Yanjuan and Chen, Fuhong and Chan, Sally and Cai, Hongxia and Zhu, Jiemin},
title = {Mobile App for Gynecologic Cancer Support for Patients With Gynecologic Cancer Receiving Chemotherapy in China: Multicenter Randomized Controlled Trial},
journal = {Journal of Medical Internet Research},
year = {2023},
doi = {10.2196/49939}
}
EUVIMED